StockNews.AI
GMAB
StockNews.AI
145 days

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

1. TIVDAK® has been approved for cervical cancer treatment in Japan. 2. This is the first ADC approved for this indication in the country.

2m saved
Insight
Article

FAQ

Why Bullish?

The approval of TIVDAK® expands GMAB's market presence, particularly in Japan. Historical approvals have led to stock price increases in biotech firms.

How important is it?

The article discusses a significant regulatory milestone for GMAB's product, which is likely to enhance future revenue and market perception.

Why Long Term?

Market expansions from drug approvals typically take time to reflect in sales and revenue, influencing long-term shareholder value.

Related Companies

BMYNVSJNJ
COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the Japan Ministry of Health, Labour and Welfare has approved TIVDAK® (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. TIVDAK is the first and only ADC to be approved for people living with cervical cancer in Japan. In recent years, cervical cancer incidence and mortality rates have increased in Japan, particularly among women un.

Related News